Bavencio Intravenous200 mg Special Drug Use - results Survey (Curatively unresectable or metastatic renal cell carcinoma)
Not Applicable
- Conditions
- Curatively unresectable or metastatic renal cell carcinoma
- Registration Number
- JPRN-UMIN000039476
- Lead Sponsor
- Merck Biopharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method